Latest Asx News

Waratah Minerals has confirmed significant extensions to its Spur Gold Corridor in NSW, revealing high-grade gold intercepts and promising porphyry copper-gold mineralisation. The expanded drilling program aims to unlock further potential in this emerging gold discovery.

Mayne Pharma shareholders have overwhelmingly approved the scheme of arrangement for Cosette Pharmaceuticals to acquire the company at $7.40 per share, despite ongoing legal challenges and regulatory approvals still pending.

Viridis Mining and Minerals is expanding its Viridion joint venture to develop a rare earth refinery in the U.S., leveraging Brazilian feedstock and proprietary technology to meet growing demand for secure, non-Chinese rare earths.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Alligator Energy advances regulatory approvals and construction preparations for its Samphire Uranium Project’s Field Recovery Trial, a critical step toward commercial production.

Estrella Resources has ramped up its manganese exploration at the Ira Miri Project in Timor-Leste with a more powerful diamond drill rig and a fresh supergene manganese outcrop discovery, setting the stage for an extensive drilling program.

First Au Limited has successfully raised $1.5 million through a private placement, exceeding its initial target, to fund its strategic acquisition of the Nimba Gold Project in Liberia.

Beacon Minerals has confirmed extensive high-grade gold mineralisation at its Iguana deposit within the Lady Ida Project, following a 201-hole drilling program. The results bolster confidence in the Stage 1 Pit mining inventory and set the stage for further exploration.

Bastion Minerals is launching a non-renounceable rights issue to raise approximately $677,721, offering shareholders three new shares for every four held. Optionholders must act quickly to exercise their options if they wish to participate.

Bastion Minerals has launched a non-renounceable rights issue to raise up to $677,721, offering eligible shareholders in Australia and New Zealand the chance to increase their holdings at a minimal price. The capital will support ongoing project evaluations and working capital needs.

Bastion Minerals Limited has announced a non-renounceable pro-rata rights issue to raise approximately $677,721 at a 50% discount to the last trading price. The funds will support ongoing project evaluation and working capital needs.

Argenica Therapeutics has reported compelling preclinical results for ARG-007, demonstrating sustained neuroprotection and functional recovery in a ferret model of moderate traumatic brain injury. These findings pave the way for clinical trials targeting a major unmet medical need.